Clinical and Molecular HepatologyKCI 등재

Clinical and Molecular Hepatology

발행처: 대한간학회
수록 기간: 2002–2026
ISSN: 2287-2728
등재 정보: KCI 등재
E-ISSN: 2287-285X

최신 호32권 1호2026.01 발행 · 논문 77편

권호: 85
논문: 1,454
조회: 1,813

32권 1호

2026.01 발행 · 논문 77편

1
2025 KASL clinical practice guidelines for management of hepatitis C
Eun Ju Cho, Chang Hun Lee, Do Seon Song, Eun Sun Jang, Nae-Yun Heo, Jae Yoon Jeong, Jung Gil Park, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung·pp. 1–52
조회 4
2
Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”
Yizi He, Haifeng He, Qi Liang, Yongzhi Xie·pp. 1–3
조회 2
3
Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”
Sisi Yang, Zhenxuan Ma·pp. 4–6
조회 1
4
Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”
Qiong Wang, Zhongqing Qian, Xiaodi Yang, Deyan Chen, Xiaojing Wang, Fuliang Chen·pp. 7–9
조회 1
5
Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Xinyi Li, Juan Yang, Sheng Zheng·pp. 10–12
조회 1
6
Letter to the editor on “Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target”
Jun Ma, Yuqian Liu, Ruiyun Guo·pp. 13–15
조회 2
7
Molecular stratification of hepatocellular carcinoma by metabolic-signaling pathways guides precision im munotherapy and TACE therapy
Binghua Li, Yanchao Xu, Yican Zhu, Yukun Zhang, Zijie Wu, Tianci Luo, Laizhu Zhang, Weiwei Hu, Decai Yu·pp. 16–20
조회 2
8
Plasma lipidomic and fungal signatures predict early mortality in acute liver failure
Jong-Won Kim, Yu Ji Kim·pp. 21–23
조회 2
9
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed·pp. 24–28
조회 0
10
Early oxidative protein modifications and gut damage/ leakiness contribute to drug-induced acute liver failure
Wiramon Rungratanawanich, Ying Qu, Andrew Holmes, Neil Kaplowitz, Byoung-Joon Song·pp. 29–33
조회 0
11
Non-contrast magnetic resonance imaging outperforms contrast-enhanced computed tomography in preoperative detection of hepatocellular carcinoma: A paired validation study
Jun Chen, Binghua Li, Decai Yu, Laizhu Zhang, Weiwei Zong, Jialin Gao, Huan Li, Leizhou Xia, Xiaoli Mai·pp. 34–37
조회 1
12
Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma
Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi·pp. 38–42
조회 1
13
Fifteen-year impact of cholecystectomy on multiple organs
Ming Zheng·pp. 43–46
조회 0
14
Optimized MASH treatment eligibility cutoffs for MRE measured liver stiffness and proton density fat fraction
Rohit Loomba, Nana Owusu, Kyle Kalutkiewicz, Jiahui Li, Alina M. Allen, Richard L. Ehman, Meng Yin·pp. 47–51
조회 0
15
HCC predictors in routine practice for patients with chronic liver diseases: Correspondence to editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunc tion associated steatotic liver disease”
Tung-Hung Su, Jia-Horng Kao·pp. 52–54
조회 0
16
Pediatric metabolic dysfunction–associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation
Jian-Gao Fan, Lu Jiang, Lan-Duoduo Du, Jing Zeng, Hui-Kuan Chu, Zhong Peng·pp. 53–68
조회 2
17
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Young Kul Jung, Hyung Joon Yim, Seong Hee Kang, Jin Mo Yang·pp. 55–57
조회 0
18
Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen·pp. 58–61
조회 1
19
Correspondence to editorial 2 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen·pp. 62–64
조회 1
20
Correspondence to editorial 3 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen·pp. 65–67
조회 1
21
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Cor respondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu·pp. 68–71
조회 1
22
Tumor- based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma
Sabrina Sidali, Claudia Campani, Jihyun An, Ju Hyun Shim, Jean-Charles Nault·pp. 69–90
조회 2
23
Correspondence to editorial on “GULP1 as a novel di agnostic and predictive biomarker in hepatocellular carcinoma”
Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim·pp. 72–74
조회 0
24
Correspondence to editorial on “CD36 Promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma”
Peng Lin, Yifei Qin, Huijie Bian, Zhi-Nan Chen, Jiao Wu·pp. 75–78
조회 0
25
Correspondence to editorial on “Molecular classifica tion of hepatocellular carcinoma based on zoned met abolic feature and oncogenic signaling pathway”
Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo·pp. 79–82
조회 1
26
Correspondence to editorial 1 on “Impacts of metabol ic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Mindie H. Nguyen, Rui Huang·pp. 83–84
조회 1
27
Correspondence to editorial 2 on “Impacts of metabol ic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Rui Huang, Mindie H. Nguyen·pp. 85–86
조회 1
28
Correspondence to editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunc tion-associated steatotic liver disease”
Seung Up Kim, Hye Won Lee·pp. 87–89
조회 2
29
Correspondence to Editorial 1 on “MET promotes he patocellular carcinoma development through the pro motion of TRIB3-mediated FOXO1 degradation”
Limin Xia, Tiantian Wang, Wenjie Huang·pp. 90–92
조회 0
30
Harnessing the microbiome: unveiling the influence of the gut microbiota on hepatobiliary cancer therapeutic strategies
Melody Yusong Li, Xue Qian Wu, Terence Kin Wah Lee·pp. 91–126
조회 2
31
Correspondence to Editorial 2 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
Limin Xia, Tiantian Wang, Wenjie Huang·pp. 93–95
조회 0
32
Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Corre spondence to the editorial on “Sex disparities in alco hol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States”
Amit G. Singal, Donghee Kim, Karn Wijarnpreecha, Pojsakorn Danpanichkul, Ju Dong Yang·pp. 96–98
조회 0
33
Revisiting unmet needs in clinical research on direct acting antiviral therapy for HCC patients: Correspon dence to letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu, Teng-Yu Lee·pp. 99–102
조회 3
34
Correspondence to letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepato cellular carcinoma”
Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim, Hyung Seok Kim·pp. 103–105
조회 0
35
Reply to correspondence on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Mattias Mandorfer, Mathias Jachs·pp. 106–108
조회 1
36
Should direct-acting antiviral be considered for all pa tients with HCV-related hepatocellular carcinoma?: Reply to correspondence on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Yu Jun Wong, Yan Ling Ong, Apichat Kaewdech·pp. 109–111
조회 1
37
GULP1: New hope for hepatocellular carcinoma: Reply to correspondence on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen·pp. 112–114
조회 0
38
Reply to correspondence on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”
Eun Ji Jang, Pil Soo Sung·pp. 115–116
조회 1
39
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
Jia-Horng Kao, Shang-Chin Huang·pp. 117–118
조회 1
40
Reply to correspondence 1 on “MET promotes he patocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
Terence Kin Wah Lee, Many Sze Man Chan·pp. 119–120
조회 0
41
Reply to correspondence 2 on “MET promotes hepato cellular carcinoma development through the promo tion of TRIB3-mediated FOXO1 degradation”
Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim, Ji Eun Han·pp. 121–124
조회 0
42
Reply to correspondence 1 on “Sex disparities in alco hol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States”
Sung-Eun Kim·pp. 125–127
조회 0
43
Stratifying cholangiocarcinoma: tumor microenvironment, molecular drivers, and novel immunotherapeutic approaches
Cindy Xinqi Liu, Carmen Chak-Lui Wong·pp. 127–155
조회 1
44
Panomics in metabolic dysfunction-associated steatotic liver disease: unravelling the drivers of disease heterogeneity
Carlos José Pirola, Silvia Sookoian·pp. 156–169
조회 2
45
Incretin-based therapies for cardio-kidney-liver-met abolic disease: the role of the liver in the modern era of chronic disease management
Harendran Elangovan, Rohit Loomba, Mark Muthiah, Jörn Schattenberg, Ming-Hua Zheng, Mazen Noureddin, Christos Mantzoros, Jacob George·pp. 170–183
조회 0
46
Targeting the innate immune system in treating hepatitis B: prospects for functional cure
Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak·pp. 184–199
조회 2
47
RAB25/GCN1 signaling promotes endoplasmic reticulum stress to mediate alcohol-associated liver disease progression
Yi Gao, Yue Zhang, Xue-Wen Liu, Zi-Bin Zhan, Ze-Hua Li, Xue-Yan Qiao, Xin-Ming Li, Xiang-Jing Liang, Kun-Hao Bai, Xian-Feng Xia, Fan-Hong Zeng, Jun Weng·pp. 200–220
조회 0
48
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production
Cheng Lu, Xin Li, Bo Tang, Yuanyuan Zhou, Dianji Tu, Junfeng Guo, Qiao Chen, Yingjie Wang, Lulu Cheng, Hongfei Jiang, Jincheng Jian, Yusong Ge, Zhanjie Hou, Xiaojie Feng, Yunxuan Feng, Jianchun Zhou, Yuanyuan Lei, Hua Diao, Lei Ran, Zhengguo Xu, Jiyin Zhou, Shiming Yang·pp. 221–238
조회 0
49
Bacteroides eggerthii ameliorates metabolic dysfunction associated steatotic liver disease through host–microbe signaling and highlights 2-hydroxyisocaproate as a potential effector
Ji Yi Choi, Moon Gyeong Yoon, Se Ha Jang, Geum Ok Baek, Hyun Sun Jung, Na-Rae Lee, Choong Hwan Lee, Ji Eun Han, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim·pp. 239–257
조회 2
50
Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-re sistant subtype with distinct molecular features
Ju-Seog Lee, Gwangil Kim, Junho Park, Jung Sun Kim, Chan Kim, Ho Yeong Lim, Won Suk Lee, Seonjeong Woo, Sung Hwan Lee, Gae Hoon Jo, Ilhwan Kim, Hyeyeong Kim, Chansik An, Sanghoon Jung, Haeyoun Kang, Beodeul Kang, Incheon Kang, Hannah Yang, So Jung Kong, Dahyeon Son, Dong Jun Shin, Woo Young Kwon, Da-Yeon Lee, Youngsoo Kim, Sohyun Hwang, Hong Jae Chon·pp. 258–275
조회 1
51
Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease
Hye-Lin Kim, Eileen L. Yoon, Jeong-Yeon Cho, Huiyul Park, Mimi Kim, Ji-Hyeon Park, Dae Won Jun·pp. 276–288
조회 1
52
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement
Hye Won Lee, Ming-Hua Zheng, Joseph Rabbat, Boyu Yang, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun J. Sanyal, Victor de Lédinghen, Philip N Newsome, Jian-Gao Fan, Laurent Castéra, Michelle Lai, Céline Fournier-Poizat, Grace Lai-Hung Wong, Mirko Zoncape, Grazia Pennisi, Angelo Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Elba Llop, Kevin Kim Jun Teh, Carmen Lara-Romero, Amon Asgharpour, Sara Mahgoub, Mandy Sau-Wai Chan, Clemence M Canivet, Manuel Romero-Gomez, Vincent Wai-Sun Wong, Seung Up Kim, Terry Cheuk-Fung Yip·pp. 289–304
조회 0
53
Comparative risk of fibrosis progression with sodium glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to intermediate fibrosis
Jonggi Choi, Daniel Fulop, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung·pp. 305–317
조회 0
54
Novel near-infrared probe for monitoring lipid peroxi dation-mediated viscosity change in ferroptotic hepa tocytes
Jiyeon Kim, Jae-Young Lee, Jeeyeon Lee, Won Kim, Le Bich Hang Pham, Taeeung Kim, Seoyoung Kim, Yun Seok Kim, Kyeongseon Kim, Hyeonwoo Lim, Wan Seob Shim, Byoungmo Kim, So-Yeol Yoo, Murim Choi, Keon Wook Kang·pp. 318–338
조회 0
55
Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nation wide cohort study with genetic risk analysis
Eun Ju Cho, Su Jong Yu, Jeong-Hoon Lee, Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Jung-Hwan Yoon, Yoon Jun Kim·pp. 339–352
조회 0
56
Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease
Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Xinrui Jin, Sherlot Juan Song, Jimmy Che-To Lai, Alice Pik-Shan Kong, Nana Peng, Xiang Xiao·pp. 353–367
조회 1
57
Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Esti mator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-as sociated steatotic liver disease”
Ho Soo Chun, Minjong Lee·pp. 368–370
조회 1
58
Can SAFE score be utilized as a universal hepatocellu lar carcinoma prediction score?: Editorial on “High Steatosis-Associated Fibrosis Estimator scores pre dict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated stea totic liver disease”
Michael Kwan-Lung Ko, Loey Lung-Yi Mak·pp. 371–373
조회 0
59
Besifovir: a viable option for long-term disease control in chronic hepatitis B: Editorial on “Switching to besi fovir in patients with chronic hepatitis B receiving te nofovir disoproxil fumarate: A randomized trial”
Wai-Kay Seto·pp. 374–376
조회 2
60
Modulation of PRL-1 in placental MSCs: A novel thera peutic strategy for hepatic fibrosis: Editorial on “Mod ulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the tran sition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis”
Lihai Jiang, Wenjie Zheng·pp. 377–380
조회 1
61
Regulation of hepatitis B virus cccDNA by metabolic pathways: Editorial on “GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome”
Hyeong-Jin Cho, Sung-Gyoo Park·pp. 381–384
조회 0
62
Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalently closed circular DNA minichromosome”
Mehrangiz Dezhbord, Kyun-Hwan Kim·pp. 385–389
조회 0
63
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?: Edi torial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-re lated cirrhosis”
Mathias Jachs, Mattias Mandorfer·pp. 390–394
조회 2
64
A non-invasive risk stratification tool for hepatitis B related liver cirrhosis: The Baveno VI-SSM combined model: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Ruiling He, Bingtian Dong, Xiaolong Qi·pp. 395–399
조회 2
65
Refining portal hypertension assessment: The clinical significance of spleen stiffness measurement in the Baveno VII Era: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in pa tients with HBV-related cirrhosis”
Do Seon Song·pp. 400–402
조회 2
66
The evolution of non-invasive strategies in cirrhosis management—from screening to precision monitoring: Editorial on “Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study”
Haiyu Wang, Jinjun Chen·pp. 403–406
조회 0
67
Editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Yu Jun Wong, Yan Ling Ong, Apichat Kaewdech, Daniel Q Huang·pp. 407–409
조회 1
68
Unveiling GULP1 as a hepatocyte-specific role for re currence: Editorial on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Ning Wang, Pengde Lu·pp. 410–412
조회 0
69
GULP1, a multifaceted diagnostic biomarker and po tential therapeutic target in hepatocellular carcinoma: Editorial on “GULP1 as a novel diagnostic and predic tive biomarker in hepatocellular carcinoma”
Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen·pp. 413–415
조회 1
70
Targeting CD36 to reinvigorate CD8+ T Cells in early stage hepatocellular carcinoma: Editorial on “CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage he patocellular carcinoma”
Valerie Chew·pp. 416–419
조회 0
71
A novel link between tumor cell metabolism and pa tient prognosis: Editorial on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”
Eun Ji Jang, Pil Soo Sung·pp. 420–422
조회 1
72
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Jia-Horng Kao, Shang-Chin Huang·pp. 423–425
조회 2
73
Type 2 diabetes as a key metabolic risk factor for ad verse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Won Kim, Heejoon Jang·pp. 426–428
조회 2
74
Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong·pp. 429–431
조회 2
75
Unveiling TRIB3: A new mediator in MET-driven hepa tocellular carcinoma progression: Editorial on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 deg radation”
Terence Kin Wah Lee, Many Sze Man Chan·pp. 432–435
조회 0
76
Uncovering the MET-TRIB3-FOXO1 axis: A novel target in MET-driven hepatocellular carcinoma: Editorial on “MET promotes hepatocellular carcinoma develop ment through the promotion of TRIB3-mediated FOXO1 degradation”
Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim, Ji Eun Han·pp. 436–438
조회 0
77
Rising burden of alcohol-associated liver disease and cancers: Insights into sex disparities and policy impli cations: Editorial on “Sex disparities in alcohol-associ ated liver disease and subtype differences in alcohol attributable cancers in the United States”
Sung-Eun Kim·pp. 439–442
조회 0